Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

Completed · Phase 3

Conditions studied: Fabry Disease

In brief

This is an open-label extension study intended to provide continued treatment with migalastat hydrochloride (HCl) for participants with Fabry disease who completed treatment of a previous migalastat HCl study. The study assessed the long-term safety and effectiveness of migalastat HCl.

Key facts

Study ID

NCT02194985

Run by

Amicus Therapeutics

People needed

84

Starts

2015-03-14

Expected to finish

2019-10-23

Last updated by the study team

2020-12-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant had completed treatment in a previous study of migalastat HCl given as a monotherapy
• Male and female participant agreed to use protocol-identified acceptable contraception
• Participant was willing to provide written informed consent and authorization for use and disclosure of Personal Health Information (PHI)

You may not qualify if…

• Participant's last available estimated glomerular filtration rate (eGFR) in the previous study was <30 milliliter (mL)/minute (min)/1.73 meters squared (m\^2); unless there was measured GFR available within 3 months of Baseline Visit, which was >30 mL/min/1.73 m\^2
• Participant had undergone, or was scheduled to undergo kidney transplantation or was currently on dialysis
• Participant had a documented transient ischemic attack, stroke, unstable angina, or myocardial infarction within the 3 months before Baseline Visit
• Participant had clinically significant unstable cardiac disease in the opinion of the investigator (for example, cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or New York Heart Association class III or IV congestive heart failure)
• Participant had a history of allergy or sensitivity to AT1001 (including excipients) or other iminosugars (for example, miglustat, miglitol)
• Participant required treatment with Glyset® (miglitol) or Zavesca® (miglustat)
• Participants with severe or unsuitable concomitant medical condition
• Participants with clinically significant abnormal laboratory value(s) and/or clinically significant electrocardiogram (ECG) findings

Where it is running

• Clinical Study Site — Atlanta, Georgia, United States
• Clinical Study Site — Kansas City, Kansas, United States
• Clinical Study Site — Grand Rapids, Michigan, United States
• Clinical Study Site — New York, New York, United States
• Clinical Study Site — Portland, Oregon, United States
• Clinical Study Site — Dallas, Texas, United States
• Clinical Study Site — Fairfax, Virginia, United States
• Clinical Study Site — Pilar, Argentina
• Clinical Study Site — Adelaide, Australia
• Clinical Study Site — Parkville, Australia
• Clinical Study Site — Vienna, Austria
• Clinical Study Site — Edegem, Belgium
• Clinical Study Site — Porto Alegre, Brazil
• Clinical Study Site — Montreal, Quebec, Canada
• Clinical Study Site — Copenhagen, Denmark
• Clinical Study Site — Cairo, Egypt
• Clinical Study Site — Garches, France
• Clinical Study Site — Lille, France
• Clinical Study Site — Florence, Italy
• Clinical Study Site — Roma, Italy
• Clinical Study Site — Suita, Osaka, Japan
• Clinical Study Site — Niigata, Japan
• Clinical Study Site — Osaka, Japan
• Clinical Study Site — Tokyo, Japan
• Clinical Study Site — Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.